Shingles vaccine shows promise for High-Risk rheumatic patients
NCT ID NCT05879419
First seen Jan 08, 2026 · Last updated May 07, 2026 · Updated 16 times
Summary
This study looks at how safe and effective the Shingrix vaccine is for people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who have a higher risk of shingles. About 2,000 participants will receive the vaccine or a placebo, and researchers will monitor disease flares, immune response, and side effects over five years. The goal is to see if the vaccine can prevent shingles without worsening their underlying condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, São Paulo, 05403-000, Brazil
Conditions
Explore the condition pages connected to this study.